Hyderabad-based drug manufacturing company Suven Life Sciences lately stepped into Indian 'NCE' Patent Wagon joining Mumbai-based drug Research Company Glenmark for receiving Indian patent for New Chemical Entity (NCE) indigenously researched and developed by the Indian company. The Chennai Patent Office issued Indian Patent No. 209540 to Suven for substituted 3-aminoalkoxyindoles as 5-HT (Serotonin) receptors against the mail-box Application No. 883/MAS/2002 filed November 28, 2002. Suven has also made a corresponding US patent filing via PCT National Phase published as US20060173193 dated August 03, 2006. According to the '193 publication, the compounds are suggested to have reach through indication over the treatment of certain CNS disorders such as, anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders e.g. Alzheimer's disease and age-related cognitive decline, ADHD (Attention Deficient Disorder/Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, chronobiological abnormalities, circadian rhythms, anxiolytic, osteoporosis, ischemic stroke, lower the risk of SIDS in young infants with low endogenous melatonin levels, reproduction, glaucoma, sleep disorders (including disturbances of Circadian rhythm) and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds are further expected to be of use in the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and Huntington's chorea. The compounds are also expected to be of use in the treatment of certain GI (Gastrointestinal) disorders such as IBS (Irritable bowel syndrome) or chemotherapy induced emesis.
Thursday, December 20, 2007
Wednesday, December 19, 2007
Continued below is list of few Indian patents issued by the Mumbai Patent Office for pharmaceutical inventions published dated December 14, 2007 vide Official Journal Issue No. 50/2007. These patents are currently open for post-grant opposition under section 25(2) of the Patents Act, 1970 for a period of one year from the date of the publication. This journal has published 245 patents issued by the Mumbai Patent Office. I have included a column for foreign equivalent of the Indian Patent, if available.
Indian Patent Number
Title of the Invention
Novel Process for preparing (+)-cis Sertraline
Bandage for Wound or Incision Closure
Heterocyclic Dihydroxypyrimidine Compounds ff Formula I
A process for the Manufacture of Optically pure (r) or (s) -5-(2-Aminopropyl) -2-Methoxybenzenes
Cadila Healthcare Ltd.
Process for the Preparation of
Spiro[(4- Cyclohexanone)- [3h]indo]-2' [1 'h]-One derivatives
Substituted Bicyclic Derivatives for the treatment of Abnormal cell Growth
An improved Process for Preparing a
Composition Containing Carotenoids &
Nutrients rich Extract from Carrots
Ajanta Pharma Ltd.
Source: Official Journal, The Patent Office Issue No. 50/2007
Below is provided the list of few Indian patents issued by the Mumbai Patent Office for pharmaceutical inventions published dated December 14, 2007 vide Official Journal Issue No. 50/2007. These patents are currently open for post-grant opposition under section 25(2) of the Patents Act, 1970 for a period of one year from the date of the publication. This journal has published 245 patents issued by the Mumbai Patent Office. I have included a column for foreign equivalent of the Indian Patent, if available.
Indian Patent Number
Title of the Invention
Farnesyl Transferase Inhibiting 1, 2-Annelated Quinoline Enantiomer
Process for Preparing Benzazole Derivatives
Applied Research Systems ARS Holding NV
Oral Pharmaceutical Composition with Controlled Release and Prolonged Absorption
New Process for the Synthesis of Perindopril and Pharmaceutical Acceptable Salts thereof
LES Laboratories Servier
Compounds Benzisoxazoles and Phenones of Formula I and Process of Preparation thereof
Injection Solution for the Treatment of Arthroses
Dr. Medadusumalli Chakravarty
A GDF-8 Analogue comprising the Natural GDF-8 Amino Acid Sequence and a Composition thereof
A Method of Preparing Pharmaceutical Implant for Controllably Releasing a Drug in a Subject
Ardana Bioscience Ltd.
Source: Official Journal, The Patent Office Issue No. 50/2007.
Go through the abstract of the US Publication No. 20070035812A1 which states “Christopher Anthony Roller is a godly entity. "Granters" had been given my powers (acquired my powers) (via God probably). These "granters" have been receiving financial gain from godly powers. These "granters" may be using their powers without morals. Chris Roller wants exclusive right to the ethical use and financial gain in the use of godly powers on planet Earth. The design of godly-products have no constraints, just like any other invention, but the ethnic consideration of it's use will likely be based on a majority vote of a group, similar to law creation. The commission I require could range from 0-100% of product price, depending on the product's value and use.” Any idea what this inventor up to, but am sure that if granted (LOL) this would be the broadest patent ever issued by any of the Patent Office.
Tuesday, December 18, 2007
Geneva-based World Intellectual Property Organization (WIPO) has granted the Indian Patent Office the status of International Search Authority (ISA) and International Preliminary Examining Authority (IPEA) joining in line of Austrian Patent Office, Australian Patent Office, Canadian Intellectual Property Office, State Intellectual Property Office of the People’s Republic of China, European Patent Office, Spanish Patent and Trademark Office, National Board of Patents and Registration of Finland, Japan Patent Office, Korean Intellectual Property Office, Federal Service for Intellectual Property, Patents and Trademarks (Russian Federation), Swedish Patent and Registration Office and United States Patent and Trademark Office. Following the development, the Indian Patent Office will now be entering into an agreement with the International Bureau of WIPO relating to the functioning as International Searching and International Preliminary Examination Authorities under the PCT which include conducting prior art search and preliminary examination, and preparing written opinions. Even the Nordic Patent Institute, an intergovernmental organization established by the governments of Denmark, Iceland and Norway will also join as International Searching Authority and International Preliminary Examining Authority from January 01, 2008 onwards.
Monday, December 17, 2007
Pfizer’s breakthrough anticancer drug Sunitinib Malate, which got marketing approval in January 26, 2006 by the Food and Drug Administration for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) has been a subject of pending mail-box Application No IN/PCT/2002/00785/DEL (the Application) filed at Delhi Patent Office. Marketed as Sutent, Sunitinib has worldwide sales of US $ 219 million in the first year of its marketing launch (source: Pfizer Annual Report 2006). The Application is filed on August 09, 2002 and subsequently published by the Patent Office on January 19, 2007 claiming earliest priority from US provisional application No. 60/182,710 filed February 15, 2000 against which Orange Book listed US Patent No. 6,573,293 and 7,125,905 are issued on June 03, 2003 and October 24, 2006 respectively.
Eli Lilly & Co. has voluntarily withdrawn its Application No. IN/PCT/00/00118 filed July 05, 2000 at Kolkata Patent Office for a stable crystalline form of osteoporosis drug Teriparatide (rDNA origin), globally marketed as Forteo with worldwide annual sales of US $ 600 million. According to the Patent Office, Lilly has withdrawn its application under section 11B (4) of the Patents Act, 1970. The Application claims earliest priority from US provisional application No. 60/069,875 filed December 18, 1997 against which US Patent No. 6,590,081 is issued on July 08, 2003. Earlier in August 2007, Kolkata Patent Office rejected Lilly’s Application for same drug following a pre-grant opposition from a Mumbai-based generic drug manufacturer USV Ltd. The rejection was made on the grounds of prior knowledge, incremental innovation and failure to establish enhancement of known efficacy. Teriparatide is a parathyroid hormone (PTH (1-34) (SEQ. ID NO:2)), a secreted 84-amino acid product of the mammalian parathyroid gland that controls serum calcium levels through its action on various tissues, including bone. Although not very sure about the Application number which got rejected by the Patent Office, but I guess it would be the Application No. IN/PCT/00/00119 filed July 26, 2000 for stabilized parenteral composition of Teriparatide (rDNA origin) claiming earliest priority from US provisional application No. 60/069,075 filed December 09, 1997 against which Orange Book listed US Patent Nos. 6,770,623 and 7,144,861 are issued. There is one more Application No. IN/PCT/00/00336 filed January 09, 2003 which is pending with the Patent Office which claims earliest priority from US provisional application Nos. 60/097,151 and 60/099, 746 filed November 08, 1998 and October 09, 1998 respectively and against which Orange Book listed US Patent Nos. 6,977,077 and 7,163,684 are issued. The Application IN/PCT/00/00336 seems to cover a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture using Teriparatide, which is unlikely to receive a patent in India, as indication and method of treatment are excluded from patentability under section 3(e) of the Patents Act, 1970. So, most likely either Lilly will too withdraw the third application or it would be humbly rejected by the Patent Office.
Friday, December 14, 2007
Mumbai-based Glenmark has lately received an Indian Patent No. 201170 for novel heterocyclic compounds as Phosphodiesterase type IV (PDV IV) inhibitors of the Formula I against the mail-box Application No. 363/MUM/2003 filed April 11, 2003 with the Mumbai Patent Office. Possibly this could be Glenmark’s first drug compound patent to be granted patent protection in India, which already has been granted US Patent No. 7,223,789. According to the ‘789 patent disclosure, the compounds are suggested to have reach through indication over the treatment of variety of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome, particularly for the treatment of asthma or chronic obstructive pulmonary disease (COPD).
Thursday, December 13, 2007
Reacting over the regulatory development of Glenmark’s submission of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration seeking approval to market generic Tarka prior to the expiration of the Orange Book listed patents, Sanofi-Aventis jointly with Abbott Laboratories has filed a civil action for the infringement of patent in the US District Court of New Jersey alleging that the proposed generic product will infringe one or more claims of Orange Book listed US Patent No. 5,721,244. Tarka is a combination extended release antihypertension oral tablet containing Trandolapril and Verapamil Hydrochloride having US $ 100 million sales in the US. It is believed that Glenmark is a First-to-File generic challenger and will be entitled to 180-day exclusivity period.